EUCTR2012-003463-22-RO进行中（未招募）1 期
MAGNITUDE - A Phase 3 Study Evaluating the Safety and Efficacy of Lambda / Ribavirin / Daclatasvir in Subjects with Chronic HCV Infection and Underlying Hemophilia who are Treatment Naïve or are Prior Relapsers to Peginterferon alfa-2a/RibavirinRevised Protocol 04 - Incorporates Amendment 05+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 11-Sep-12) - MAGNITUDE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Infection with the hepatitis C virus (HCV) with underlying hemophilia
- •Males 18 years of age and above
- •Have not been previously treated with an interferon
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •or human immunodeficiency virus (HIV)
- •Do not have a serious liver, psychiatric, blood, thyroid, lung, heart or
- •eye disease
- •Presence of Bethesda inhibitor
- •Current evidence of or history of portal hypertension
研究者
相似试验
进行中（未招募）
不适用
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBVEUCTR2012-003463-22-ESBristol-Myers Squibb International Corporation130
已完成
3 期
MAGNITUDE-A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBV;Revised Protocol 01 Incorporates Amendment 02 and Administrative Letter 01 and 02;+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 11-Sep-12)Chronic HepatitisHemophiliaNL-OMON39678Bristol-Myers Squibb10
进行中（未招募）
不适用
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBVChronic Hepatitis C Virus Infection (Genotype 1b, 2, 3, 4)MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003463-22-NLBristol-Myers Squibb International Corporation130
进行中（未招募）
1 期
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV inTreatment Naïve Subjects with Chronic HCV Infection, who haveUnderlying Mild or Moderate Hemophilia or Patients who are PriorRelapsers to Pegylated interferon alfa/RBVChronic Hepatitis C Virus Infection(Genotype 1b, 2, 3, 4)MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003463-22-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO130
进行中（未招募）
不适用
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR MutationMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-000604-41-IEVertex Pharmaceuticals Incorporated1,000